FDA Expands Elevidys Approval, Bringing Duchenne Muscular Dystrophy Gene Therapy Into a More Complex Regulatory Arena

For families of patients with Duchenne muscular dystrophy, time is often not an abstract concept, but a calendar marked by the gradual loss of muscle strength, walking ability, and respiratory function. On June 20, 2024, the U.S. FDA expanded the approval scope of Elevidys, making this one-time gene therapy eligible for use across a broader age range and disease stages, and once again placing the evidence threshold for rare disease treatments at the center of regulatory debate.

The FDA announced that Elevidys may be used in Duchenne muscular dystrophy patients aged 4 years and older who have a confirmed mutation in the DMD gene. Among them, the indication for ambulatory patients was converted from its previous accelerated approval to traditional approval; non-ambulatory patients received accelerated approval, based on detectable expression of Elevidys micro-dystrophin after treatment. This differs from some market interpretations that the “non-ambulatory population was rejected.” According to the FDA announcement and approval letter, this population did not receive traditional approval, but was placed under the accelerated approval pathway, where clinical benefit still needs to be confirmed.

Elevidys was developed by Sarepta Therapeutics and is a gene therapy for Duchenne muscular dystrophy. Because of genetic mutations, DMD patients cannot produce normal dystrophin, causing muscle cells to become damaged and degenerate over time. Elevidys is designed to deliver, through a viral vector, a genetic construct capable of expressing micro-dystrophin, in an attempt to fill the most critical molecular gap in the disease. However, whether micro-protein expression can be stably translated into long-term functional benefits for patients is precisely the hardest question for therapies of this kind to answer.

The importance of this decision lies in the FDA’s different evidence judgments for different patient populations. For ambulatory patients, the regulator considered the existing data sufficient to support traditional approval; for non-ambulatory patients, the FDA accepted a surrogate endpoint as the basis for accelerated approval, but required subsequent clinical trials to provide more complete proof of efficacy. The approval letter lists relevant clinical trial numbers, including NCT05096221 and NCT04626674, and also requires Sarepta to complete a randomized controlled confirmatory trial in non-ambulatory DMD patients. The trial completion deadline is May 30, 2027, and the final report must be submitted by November 30, 2027.

This approval profile, with “one half more solid and one half still under validation,” reflects the real-world pressure in rare disease drug review. Duchenne muscular dystrophy has a severe disease course and limited treatment options, and waiting for large long-term trials to finish may cause some patients to miss a treatment window. But gene therapies are expensive, have durable effects, and require long safety monitoring periods, so regulators also cannot equate improvement in a biomarker directly with improvement in patients’ lives.

For Sarepta, the expanded label undoubtedly changes the commercial landscape for Elevidys and increases the pressure on the company to deliver subsequent evidence. Traditional approval helps stabilize the market for ambulatory patients; including non-ambulatory patients under accelerated approval extends treatment access to later stages of disease, but at the same time leaves unresolved clinical questions in front of the company, physicians, and regulators.

The key question ahead is not only how many patients can receive treatment, but whether confirmatory trials can prove that micro-dystrophin expression brings measurable, sustained, and meaningful functional benefits for patients. Elevidys’ expanded approval is therefore not only a single-product event, but also a larger test: as gene therapy moves into the clinical reality of rare diseases, how can the regulatory system draw a trustworthy boundary between hope and evidence?